Literature DB >> 20582394

Volumetric modulated arc therapy for advanced pancreatic cancer.

Wietse Eppinga1, Frank Lagerwaard, Wilko Verbakel, Ben Slotman, Suresh Senan.   

Abstract

BACKGROUND: Intensity-modulated radiotherapy (IMRT) allows for improved sparing of organs at risk (OARs) in advanced pancreatic cancer. A planning study evaluated if volumetric modulated arc therapy (RapidArc [RA]) could be used as an alternative to IMRT in such cases. PATIENTS AND METHODS: In ten patients, five-field IMRT (5f-IMRT) plans with fixed gantry positions were compared to RA plans using similar constraints for planning target volume (PTV) and OARs. PTV coverage, conformity indices (CI), and OAR doses were compared. One patient was treated using RA and calculated dose distributions were measured in coronal planes in a solid-water phantom.
RESULTS: RA plans showed superior mean CI of 1.09 +/- 0.02 (+/- 1 SD [standard deviation]) versus 1.20 +/- 0.10 in 5f-IMRT (p = 0.003). Both techniques achieved similar sparing of the right kidney, but RA significantly reduced left kidney doses with V(15) of 7.2% +/- 5.3% and 15.9% +/- 11.1%, respectively; p = 0.02. RA modestly decreased mean doses to liver (13.8 vs. 15.1 Gy; p = 0.003), stomach (16.7 vs. 17.9 Gy; p = 0.017), small bowel (19.8 vs. 22.1 Gy; p < 0.001), and duodenum (38.8 vs. 41.9 Gy; p = 0.004). Film dosimetry revealed excellent agreement between calculated and measured dose distributions. The delivery time for RA was < 3 min.
CONCLUSION: RA planning achieved superior CI for pancreatic tumors compared to 5f-IMRT, and modestly reduced OAR doses. Fast treatment delivery using RA may decrease the risk of intrafractional organ motion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582394     DOI: 10.1007/s00066-010-2094-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  37 in total

Review 1.  Partial irradiation of the liver.

Authors:  L A Dawson; R K Ten Haken; T S Lawrence
Journal:  Semin Radiat Oncol       Date:  2001-07       Impact factor: 5.934

2.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

3.  The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.

Authors:  Kathy L Baglan; Robert C Frazier; Di Yan; Raywin R Huang; Alvaro A Martinez; John M Robertson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

4.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

5.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.

Authors:  Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

6.  Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity.

Authors:  Jerome C Landry; Gary Y Yang; Joseph Y Ting; Charles A Staley; William Torres; Natia Esiashvili; Lawrence W Davis
Journal:  Med Dosim       Date:  2002       Impact factor: 1.482

7.  Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution.

Authors:  Mary Feng; James M Balter; Daniel Normolle; Saroja Adusumilli; Yue Cao; Thomas L Chenevert; Edgar Ben-Josef
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-22       Impact factor: 7.038

8.  Histological features of lymph node metastasis in patients with biliary tract cancer.

Authors:  Haruki Morimoto; Tetsuo Ajiki; Takashi Ueda; Hidehiro Sawa; Tsunenori Fujita; Ippei Matsumoto; Takeo Yasuda; Yasuhiro Fujino; Yoshikazu Kuroda; Yonson Ku
Journal:  J Surg Oncol       Date:  2008-04-01       Impact factor: 3.454

9.  A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Authors:  Saila P Kauhanen; Gaber Komar; Marko P Seppänen; Kirsti I Dean; Heikki R Minn; Sami A Kajander; Irina Rinta-Kiikka; Kalle Alanen; Ronald J Borra; Pauli A Puolakkainen; Pirjo Nuutila; Jari T Ovaska
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

Review 10.  Radiotherapy in pancreatic cancer.

Authors:  Gunther Klautke; Thomas B Brunner
Journal:  Strahlenther Onkol       Date:  2008-11-19       Impact factor: 3.621

View more
  21 in total

1.  Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial.

Authors:  Sergio Maluta; Moshe Schaffer; Fabio Pioli; Stefano Dall'oglio; Stefano Pasetto; Pamela M Schaffer; Bernard Weber; Maria Grazia Giri
Journal:  Strahlenther Onkol       Date:  2011-09-19       Impact factor: 3.621

Review 2.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

3.  Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer.

Authors:  Marlies Pasler; Dietmar Georg; Holger Wirtz; Johannes Lutterbach
Journal:  Strahlenther Onkol       Date:  2011-11-29       Impact factor: 3.621

4.  [Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis].

Authors:  T Brunner
Journal:  Strahlenther Onkol       Date:  2012-04       Impact factor: 3.621

5.  Chest wall radiotherapy with volumetric modulated arcs and the potential role of flattening filter free photon beams.

Authors:  S Subramaniam; S Thirumalaiswamy; C Srinivas; G A Gandhi; M Kathirvel; K K Kumar; S Mallik; M Babaiah; Y Pawar; A Clivio; A Fogliata; P Mancosu; G Nicolini; E Vanetti; L Cozzi
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

6.  RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma.

Authors:  G Z Gong; Y Yin; L G Xing; Y J Guo; T Liu; J Chen; J Lu; C Ma; T Sun; T Bai; G Zhang; R Wang
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

7.  Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis.

Authors:  Rachit Kumar; Aaron T Wild; Mark A Ziegler; Ted K Hooker; Samson D Dah; Phuoc T Tran; Jun Kang; Koren Smith; Jing Zeng; Timothy M Pawlik; Erik Tryggestad; Eric Ford; Joseph M Herman
Journal:  Med Dosim       Date:  2013-03-27       Impact factor: 1.482

8.  Impact of gantry rotation time on plan quality and dosimetric verification--volumetric modulated arc therapy (VMAT) vs. intensity modulated radiotherapy (IMRT).

Authors:  Marlies Pasler; Holger Wirtz; Johannes Lutterbach
Journal:  Strahlenther Onkol       Date:  2011-11-29       Impact factor: 3.621

9.  Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.

Authors:  F Alongi; M Bignardi; I Garassino; S Pentimalli; R Cavina; P Mancosu; G Reggiori; A Poletti; D Ferrari; P Foa; A Bigoni; A Dragonetti; P Salvatori; O Spahiu; A Fogliata; L Cozzi; A Santoro; M Scorsetti
Journal:  Strahlenther Onkol       Date:  2011-12-24       Impact factor: 3.621

10.  Node-positive left-sided breast cancer: does VMAT improve treatment plan quality with respect to IMRT?

Authors:  M Pasler; D Georg; S Bartelt; J Lutterbach
Journal:  Strahlenther Onkol       Date:  2013-03-24       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.